šŸ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: ImCheck Therapeutics

1.1 - Company Overview

ImCheck Therapeutics Logo

ImCheck Therapeutics

Headquarter: France
Founded: 20XXšŸ”’
Employees: 100-500šŸ”’
šŸŒ Website

Company description

  • Provider of immunomodulatory antibody therapies and discovery services targeting cancer and immune-related diseases, including BTN3A monoclonal antibodies that modulate Ī³9Ī“2/Ī³9VĪ“2 T cells: ICT01 to activate against advanced solid tumors; ICT41 to activate for viral, bacterial, and parasitic infections; and ICT21 to antagonize dysfunctional activation in autoimmune diseases.

Products and services

  • ICT01: Humanized anti-BTN3A antibody that selectively activates Ī³9Ī“2 T cells, generating a broad immune response against advanced solid tumors
  • ICT21: Anti-BTN3A antagonist designed to inhibit dysfunctional activation of Ī³9Ī“2 T cells associated with autoimmune diseases
  • ICT41: Humanized anti-BTN3A antibody that activates Ī³9VĪ“2 T cells to combat viral, bacterial, and parasitic infections through multiple immune pathways

Key contacts

šŸ”’
šŸ”’

Financial details

šŸ”’

1.2 - Competitors and similar companies to ImCheck Therapeutics

XBiotech Logo

XBiotech

HQ: United States Website
  • Description: Provider of antibody therapy development as a biopharmaceutical company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full XBiotech company profile ā†’
OncoPep Logo

OncoPep

HQ: United States Website
  • Description: Provider of investigational multi-peptide therapeutic cancer vaccines and adoptive T cell therapies, including PVX-410 for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM); MTAA-420 for multiple myeloma; and second-generation vaccines PVX-024/PVX-510 to enhance the first iteration of OncoPep's vaccine and expand to additional HLA subtypes, such as HLA-A24.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full OncoPep company profile ā†’
NexImmune Logo

NexImmune

HQ: United States Website
  • Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full NexImmune company profile ā†’
Selexis Logo

Selexis

HQ: Switzerland Website
  • Description: Provider of proprietary technology and highly specialized expertise for mammalian (suspension-adapted CHO-K1) cell line generation, helping translate scientific innovation into life-saving medicines for patients.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Selexis company profile ā†’
OncoSec Logo

OncoSec

HQ: United States Website
  • Description: Provider of oncology gene therapies and delivery technologies using electroporation to create transient cell membrane pores for improved IL-12 uptake. Offers TAVO (tavokinogene telseplasmid) intratumoral IL-12 therapy, Visceral Lesion Applicator for internal tumors, a plasmid DNA delivery platform, clinical trials to advance its technology, and global partnerships.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full OncoSec company profile ā†’
šŸ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

šŸ”’
šŸ”’
šŸ”’
šŸ”’ View all strategic buyers with complete profiles
Start Free Trial ā†’

2.2 - Strategic buyer groups for ImCheck Therapeutics

šŸ”’

Buyer group 1: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 2: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 3: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial ā†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to ImCheck Therapeutics

2.2 - Growth funds investing in similar companies to ImCheck Therapeutics

šŸ”’ View all growth equity funds with complete profiles
Start Free Trial ā†’

4 - Top valuation comps for ImCheck Therapeutics

4.2 - Public trading comparable groups for ImCheck Therapeutics

šŸ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial ā†’

4.3 - M&A Transactions similar to ImCheck Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
šŸ”’ View all M&A transactions with complete deal terms
Request Free Trial Now ā†’

Frequently Asked Questions

About ImCheck Therapeutics

What does ImCheck Therapeutics do?

ImCheck Therapeutics is a provider of immunomodulatory antibody therapies and discovery services targeting cancer and immune-related diseases, including BTN3A monoclonal antibodies that modulate Ī³9Ī“2/Ī³9VĪ“2 T cells: ICT01 to activate against advanced solid tumors; ICT41 to activate for viral, bacterial, and parasitic infections; and ICT21 to antagonize dysfunctional activation in autoimmune diseases.

Who are ImCheck Therapeutics's competitors?

ImCheck Therapeutics's competitors and similar companies include XBiotech, OncoPep, NexImmune, Selexis, and OncoSec.

Where is ImCheck Therapeutics headquartered?

ImCheck Therapeutics is headquartered in France.

How many employees does ImCheck Therapeutics have?

ImCheck Therapeutics has 1,000 employees šŸ”’.

When was ImCheck Therapeutics founded?

ImCheck Therapeutics was founded in 2010 šŸ”’.

What sector and industry vertical is ImCheck Therapeutics in?

ImCheck Therapeutics is in the Enterprise Software šŸ”’ sector and industry

M&A Buyers & Acquirers for ImCheck Therapeutics

Who are the top strategic acquirers in ImCheck Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in ImCheck Therapeutics's sector include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which M&A buyer groups are most relevant for ImCheck Therapeutics?

Top strategic M&A buyers groups and sectors for ImCheck Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ , ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Financial Investors investing in ImCheck Therapeutics's sector and industry vertical

Which are the top PE firms investing in ImCheck Therapeutics's sector and industry vertical?

Top PE firms investing in ImCheck Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top buyout funds acquiring in ImCheck Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in ImCheck Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top growth equity funds investing in companies in ImCheck Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to ImCheck Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Valuation benchmarks of companies in ImCheck Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for ImCheck Therapeutics?

The key public trading comparables and valuation benchmarks for ImCheck Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which are the key trading comparable groups for ImCheck Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for ImCheck Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in ImCheck Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for ImCheck Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in ImCheck Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in ImCheck Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for ImCheck Therapeutics